<DOC>
	<DOCNO>NCT02291588</DOCNO>
	<brief_summary>This first-in-human , multicenter study evaluate administration placebo AMG 811 single subcutaneous intravenous dose subject SLE</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics AMG 811 Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Diagnosis SLE ncluding positive antinuclear antibody ( ANA ) test least 6 month randomization ; concurrent SLE pharmacologic regimen ( include leflunomide , methotrexate , antimalarial ) stable least 30 day randomization ; prednisone ≤ 20 mg/day ( equivalent ) permit ; 1 increase decrease ≤ 5mg/day prednisone equivalent allow within 30 day randomization Subjects , clinical judgment investigator , severe disease ; subject least 1 BILAG ' A ' score 2 BILAG ' B ' score organ system screen ; sign symptoms viral bacterial infection within 30 day study randomization , recent history repeat infection , evidence liver disease ; concurrent receipt mycophenolate mofetil azathioprine ; prior administration another biologic primarily target immune system within 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>